Κρυπτογενές ισχαιμικό έμφρακτο Γεώργιος Ντάιος Επίκουρος Καθηγητής Παθολογίας, Πανεπιστήμιο Θεσσαλίας 3 ο Συνέδριο ΙΜΕΘΑ Αθήνα, 24/4/2014.

Slides:



Advertisements
Similar presentations
Evidence-based approach to imaging-based thrombolysis beyond the 4
Advertisements

Antiplatelet and anticoagulant therapy in stroke prevention
Valvular Heart Disease
Πόσο σίγουροι είμαστε για το όφελος της ενδαρτηρεκτομής; Γεώργιος Ντάιος Παθολογική Κλινική & Ομώνυμο Ερευνητικό Εργαστήριο Ιατρική Σχολή Πανεπιστημίου.
Is Carotid Stenting an Option for Treatment of Carotid Stenosis? Joint Hospital Surgical Grand Round WH WONG Queen Mary Hospital.
Ass. Professor of Cardiology
Monitoring: What, when and how long? George Ntaios University of Thessaly, Larissa, Greece.
A short introduction on
Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370: Presented by Kris Huston | July 21, 2014.
Intraoperative Echocardiography Harold G. Jackson II Tulane University Anesthesiology Elective.
Κρυπτογενή εγκεφαλικά έμφρακτα:
Anticoagulant in Ischemic Stroke : An Evidence based medicine approach.
Embolic Stroke Emily Chang PGY-3 May 4, Definition Particles of debris that originate from another source that lead to blockage of arterial perfusion.
ESUS: Embolic Strokes of Undetermined Source
Atrial fibrillation wavelets propagating in different directions disorganised atrial depolarisation without effective atrial contraction f waves
The value of echocardiography in stroke management Asjid Qureshi, Specialist registrar to Dr S Nussey.
FERNE/EMRA The Management of ED TIA Patients: What is the optimal outpatient work-up, treatment and disposition?
Transthoracic Echocardiography in Cerebrovascular Disease Nisha I Parikh, MD MPH Noninvasive Imaging Conference May 14 th 2008.
Dr Avinash Haridas Pillai
Valvular Heart DISEASE
Secondary prevention after a TIA or ischemic stroke.
Mitral Valve Disease Prof JD Marx UFS January 2006.
University of Thessaly, Larissa, Greece
1 Statin treatment is associated with improved prognosis in patients with AF-related stroke G. Ntaios, V. Papavasileiou, K.Makaritsis, A.Karagiannaki,
1 MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical.
UNEXPECTED CAUSE(S) OF CEREBRAL MICROEMBOLISATION INVESTIGATED BY TRANSCRANIAL DOPPLER DUPLEX COLOUR SONOGRAPHY Muriel SPRYNGER Cardiology-Angiology CHU.
Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.
Jim Hoehns, Pharm.D.. Lancet 2013;382: Albers G et al. Chest. 2001; 119 (suppl): 300S. Ischemic stroke 85% Hemorrhagic stroke 15% Other 5% Cryptogenic.
Clinical Overview Director, Stanford Stroke Center Stanford University Palo Alto, California Gregory W. Albers, MD.
University of Thessaly, Larissa, Greece
Stroke in the era of NOACs George Ntaios MD, MSc (Stroke Medicine), PhD University of Thessaly, Greece Oslo 11/12/2015.
Dr. Meg-angela Christi M. Amores
Κρυπτογενή εγκεφαλικά έμφρακτα Γεώργιος Ντάιος Παθολογική Κλινική, Πανεπιστήμιο Θεσσαλίας.
Long term complications of MVP. In most studies, MVP has a complication rate of less than 2 percent per year 2,15. The age-adjusted survival rate in men.
Stroke Research 2016 Jeanne Carroll, RN, BA, CCRC 2 Ivorine Yu, PhD 1 Fen-Lei Chang, MD, PhD 1,2,3 1 Indiana University School of Medicine – Fort Wayne.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
CRYPTOGENIC STROKE Epidemiology, Pathophysiology, Diagnosis and Follow-Up Reveal LINQTM Insertable Cardiac Monitoring System Reveal LINQTM Insertable.
Cardioembolic Stroke: Diagnosis and Management
Prevention of thromboembolism in AF ACC/AHA/ESC Guidelines Jin-Bae Kim, MD, PhD Arrhythmia Service, Division of Cardiology Cardiovascular Center, Kyung.
Causes of Heart Valve Dysfunction Congenital defects (bicuspid aortic valve) Infections (rheumatic fever and bacterial endocarditis Coronary artery disease.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
Atrial Fibrillation Jay H. Lee, MD Denver Health Medical Center Wednesday 2 July 2008.
Embolic Strokes of Undetermined Source
Γεώργιος Ντάιος Παθολογική Κλινική, Πανεπιστήμιο Θεσσαλίας Διαχείριση αντιπηκτικής αγωγής εν όψει προγραμματισμένων επεμβατικών πράξεων.
MANAGEMENT OF STROKE ANTICOAGULATION Latifa Oukerraj, Jamila Zarzur Cardiologie B, CHU Ibn Sina Rabat Printemps de cardiologie Marrakech 8éme Edition.
Causes of Heart Valve Dysfunction
ESUS in the Athens Stroke Registry George Ntaios University of Thessaly, Larissa/Greece Barcelona, 08 June 2016.
IN THE NAME OF GOD Dr. h-kayalha Anesthesiologist.
CARDIOEMBOLIC STROKE Debasis Das, MD, FACC Interventional Cardiologist CHI St. Vincent Heart Clinic Arkansas April 25, 2015.
Initiating prevention after acute stroke in NVAF and beyond George Ntaios University of Thessaly, Larissa/Greece.
Γεώργιος Ντάιος Παθολογική Κλινική Πανεπιστημίου Θεσσαλίας Κλινικές περιπτώσεις με μη βαλβιδική κολπική μαρμαρυγή.
Afternoon Report PETER VAYALIL. Case Presentation 63 y/o female with history of DM2, morbid obesity, COPD, and likely sleep apnea presented with significant.
© free-ppt-templates.com 2017 AHA/ACC Focused Update of Valvular Heart Disease Guideline of 2014 DR. OMAR SHAHID TR CARDIOLOGY SZH.
Cryptogenic Stroke and AF
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
Pathophysiology of atrial fibrillation and associated stroke
Difficult situations in anticoagulation after stroke
Investigations of the Cardiovascular system
Anticoagulation in Stroke.
Novel oral anticoagulants in comparison with warfarin
Atrial fibrillation (AF) and flutter
ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
Etiology of stroke Sanjeeva Onteddu.
Fibrillazione atriale
Stroke and TIA Evaluations in Neurologically Underserved Regions Ganesh Asaithambi, MD John Nasseff Neuroscience Specialty Clinic 11/8/18.
Study Background and Rationale Updated October 24, 2018
AMYLOID AND AF: WHAT ARE WE MISSING?
Which NOAC and When for Stroke Prevention in AF?
Presentation transcript:

Κρυπτογενές ισχαιμικό έμφρακτο Γεώργιος Ντάιος Επίκουρος Καθηγητής Παθολογίας, Πανεπιστήμιο Θεσσαλίας 3 ο Συνέδριο ΙΜΕΘΑ Αθήνα, 24/4/2014

Disclosures Scholarships: European Stroke Organization; Hellenic Society of Atherosclerosis. Honoraria: Medtronic; Quintiles; CHUV; Belgian Stroke Council; Boehringer-Ingelheim. Speaker fees: Sanofi; Boehringer-Ingelheim, Galenica Support to attend conferences: Bayer; Sanofi-Aventis; Pfizer; Lundbeck; Boehringer- Ingelheim; Galenica; Elpen; Bristol Myers Squibb. Participation in trials: – NAVIGATE-ESUS / National Coordinator (Greece) – GLORIA-AF / Sub-investigator (Larissa). – FOURIER / Principal investigator (Larissa). – ENOS / National Coordinator (Greece). – EBBINGHAUS / Principal Investigator (Larissa). – PRECIOUS / National Coordinator (Greece). – BIOSIGNAL / Principal Investigator (Larissa). – PREVISE / Principal investigator (Larissa).

TOAST classification Adams. Stroke 1993

TOAST classification ?

Cryptogenic stroke: what actually do you mean? Cryptogenic Not investigatedMultiple causesReally cryptogenic

Cryptogenic stroke & antithrombotic treatment ♀, 77yrs Right hemiparesis - aphasia Arterial hypertension LDL: 83mg/dl

Cryptogenic stroke & antithrombotic treatment Which antithrombotic ? Aspirin Triflusal Clopidogrel Aspirin & Clopidogrel Acenocoumarol Apixaban Dabigatran Rivaroxaban

AHA Stroke Guidelines Furie. Stroke 2010

Cryptogenic stroke: not rare

Cryptogenic stroke: not innocent Ntaios, Vemmos. Eur J Neurol. 2014; 21:

Hart. Lancet Neurol 2014; 13: 429–38 ESUS: Embolic Strokes of Undetermined Source

Lacunar strokes are not embolic

ESUS: Embolic Strokes of Undetermined Source

ESUS: potential causes Hart. Lancet Neurol 2014; 13: 429–38

ESUS: diagnostic criteria Hart. Lancet Neurol 2014; 13: 429–38 Stroke detected by CT or MRI that is not lacunar. Absence of extracranial or intracranial atherosclerosis causing >50% luminal stenosis in arteries supplying the area of ischemia. No major-risk cardioembolic source of embolism ( permanent or paroxysmal AF, sustained atrial flutter, intracardiac thrombus, prosthetic cardiac valve, atrial myxoma or other cardiac tumours, mitral stenosis, recent (<4 weeks) MI, LVEF<30%, valvular vegetations, or infective endocarditis ). No other specific cause of stroke identified.

ESUS: diagnostic algorithm Hart. Lancet Neurol 2014; 13: 429–38 Brain CT or MRI 12-lead ECG Precordial echocardiography Imaging of both extra- and intracranial arteries supplying the area of brain ischemia Cardiac monitoring for ≥24hours with automated rhythm detection

Sanna. N Engl J Med 2014;370: CRYSTAL-AF

30.0% vs. 3.0% CRYSTAL-AF Sanna. N Engl J Med 2014;370:

EMBRACE Gladstone. N Engl J Med 2014;370:

EMBRACE Gladstone. N Engl J Med 2014;370:

ESUS in the Athens Stroke Registry Ntaios, Vemmos. Stroke 2015; 46:176-81

Mitral valve Myxomatous valvulopathy with prolapse5 (1.8%) Mitral annular calcification8 (2.9%) Aortic valve Aortic valve stenosis3 (1.1%) Calcific aortic valve12 (4.4%) Non-atrial fibrillation atrial dysrhythmias and stasis Atrial asystole and sick-sinus syndrome3 (1.1%) Atrial high-rate episodes7 (2.6%) Atrial appendage stasis with reduced flow velocities or spontaneous echodensities6 (2.2%) Atrial structural abnormalities Atrial septal aneurysm10 (3.6%) Chiari network0 Left ventricle Moderate systolic or diastolic dysfunction (global or regional)42 (15.4%) Ventricular non-compaction12 (4.4%) Endomyocardial fibrosis1 (0.4%) Covert paroxysmal atrial fibrillation (detected during follow-up) Atrial fibrillation detected on stroke recurrence-3030 (11.0%) Atrial fibrillation detected on monitoring during follow-up50 (18.3%) Atrial fibrillation not confirmed but strongly suspected38 (13.9%) Cancer-associated Covert non-bacterial thrombotic endocarditis1 (0.4%) Tumor emboli from occult cancer2 (0.8%) Arteriogenic emboli Aortic arch atherosclerotic plaques9 (3.3%) Cerebral artery non-stenotic plaques with ulceration29 (10.6%) Paradoxical embolism Patent foramen ovale11 (4.0%) Atrial septal defect3 (1.1%)

ESUS: 5-yrs stroke recurrence Ntaios, Vemmos. Stroke, in revision

AHA Stroke Guidelines Furie. Stroke 2010

NAVIGATE- ESUS Rivaroxaban 15mg 1x1 Aspirin 100mg 1x1 R

RESPECT - ESUS Dabigatran 110/150 1x2 Aspirin 100mg 1x1 R

-Everybody gets happy! -Half stroke patients get an anticoagulant!

Take-home messages Cryptogenic  ESUS ~10% of all stroke patients ESUS needs a complete (?) diagnostic work-up Covert AF is the most common underlying factor High(est?) recurrence rate NOACs to replace antiplatelets?

Join the Hellenic Stroke Organization !